We are launching a laboratory developed test for precision dose monitoring of Natalizumab (#Tysabri)! Our novel assay addresses the substantial unmet need for physicians to more effectively monitor biologic drug levels in patients with #MultipleSclerosis #PML #PrecisionMedicine

The commercial availability of #moNATor is ever so important given recent Biogen MS announcements showing a significant reduction in #PML risk for patients on extended interval dosing (EID). Follow Abreos Biosciences for the latest updates on our product launch and #MultipleSclerosis

If you are a #MultipleSclerosis patient on Tysabri, take the guessing game out of dosing regimen with #moNATor, launching NEXT WEEK! Go to abreosbio.com to pre-order your drug monitoring kit now.

So excited to be announcing the launch of our first commercial product! Available TODAY! Order your Tysabri laboratory diagnostic test at abreos.com story.cd/AAJze6

See what #MultipleSclerosis doctors are saying about #moNATor: “...recent data regarding #Tysabri dosing interval extension and PML risk reduction is a major advance. The moNATor assay provides another tool to the clinician which may help to optimize patient care” -Dr. John Foley

Thank you to Multiple Sclerosis News Today for sharing Abreos Biosciences's exciting launch of our FDA-cleared LDT for the drug monitoring of #Tysabri!!

Announcing partnership with ResearchDx, a CLIA approved, CAP accredited companion diagnostics organization based in Irvine, CA to help design and develop products using Abreos' patented Veritope technology! story.cd/AAJ3XI

Abreos Biosciences enters research collaboration with the FDA’s Center for Drug Evaluation and Research (CDER) story.cd/AALNHo

Big congrats to Abreos Biosciences for winning the #PrecisionMedicine #PMWC18 Silicon Valley Most Promising Company Award. MedTech Innovator 2017 finalist doing great things for patients! x.com/PMWCintl/statu…

3 days to apply! Seeking the best device, diagnostic, or digital companies in the world to compete for $500K+ in cash prizes in the medtech industry's premiere accelerator. Founder friendly. No equity or participation fee. Apply now: medtechinnovator.org/apply

Proud to announce that Abreos was selected as the winner of the #PMWC18 Silicon Valley Most Promising Company Award! Thank you to all that attended the event, we are excited to bring important #PrecisionMedicine technologies to patients.

Extending Dosing Intervals Reduces Deadly Side Effect Risk from Popular Multiple Sclerosis Drug #PrecisionMedicine #MultipleSclerosis nyulangone.org/press-releases…

"...when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent."

Don’t miss our last round of company presentations from Amarantus BioScience, Histogen, Abreos Biosciences, Denovo Biopharma, MDI Therapeutics, and Rapid Novor Inc. The first session starts in 5 minutes! #BiocomPartnering

Biocom member Abreos Biosciences (winner of our 2016 Five in 5 challenge) presents on their mission to become the trusted source for biologic drug monitoring & create value for all healthcare stakeholders by ensuring that patients have the right drug at the right dose #BiocomPartnering

Attending AAN? Come by and visit us at booth #1260! We'll be giving out a sweet surprise to the first visitors... Exhibitor hours start Sunday, April 22nd at 11:30 AM.

Attending #AAN2018? Come by and visit us at booth #1260! We'll be giving out a sweet surprise to the first visitors... Exhibitor hours start Sunday, April 22nd at 11:30 AM. American Academy of Neurology #Neurology

Are you at #AAN2018? Stop by and visit #SpringboardAccelerator grad Abreos Biosciences (Booth #1260)! #MadeInSanDiego #Neurology x.com/AbreosBio/stat…

There once was a company in LA Giving out something sweet during the day Twas only a few Come one, come all and view Booth #1260 today! American Academy of Neurology The Cravory #AAN2018 #Neurology